Fatigue News and Research

RSS

Mayo Clinic residents attribute traffic incidents to fatigue and distress

It appears that long, arduous hours in the hospital are causing more than stress and fatigue among doctors-in-training -- they're crashing, or nearly crashing, their cars after work, according to new Mayo Clinic research. Nearly half of the roughly 300 Mayo Clinic residents polled during the course of their residencies reported nearly getting into a motor vehicle crash during their training, and about 11 percent were actually involved in a traffic accident.

19 Dec 2012

EMD Serono's L-BLP25 Phase III NSCLC trial does not meet primary endpoint

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).

19 Dec 2012

Study: Half of the benefit of taking sleeping pills comes from the placebo effect

Half of the benefit of taking sleeping pills comes from the placebo effect, according to a major new study published in the British Medical Journal.

19 Dec 2012

Global travel, climate warming could create right conditions for chikungunya outbreaks in the U.S.

Global travel and climate warming could be creating the right conditions for outbreaks of a new virus in this country, according to a new Cornell University computer model.

18 Dec 2012

Study investigates muscle weakness in mouse model of Down syndrome

It is well known that people with Down syndrome (DS) suffer from marked muscle weakness. Even the simple tasks of independent living, such as getting out of a chair or climbing a flight of stairs, can become major obstacles. This can reduce the quality of life for those with DS and lead to a loss of independence. Now, a new study sheds light on some of the suspected causes of muscle weakness.

18 Dec 2012

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

At-home exercise regimen sufficient to increase cancer patients' mobility and reduce fatigue

It has been known for some time that exercise is important for cancer patients, but few studies have looked at the practicality of exercise programs and whether even a minimal workout can help.

14 Dec 2012

Massage could ease distress of brain cancer

Massage therapy can significantly reduce distress levels in individuals with brain tumors, indicating its potential use to improve quality of life in this population, report US researchers.

13 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Study finds silent reading difficulties in glaucoma patients

Better strategies are needed to help glaucoma patients cope with difficulty reading. According to a new scientific study published in Investigative Ophthalmology & Visual Science, adults with glaucoma read slower when reading silently for long periods of time and are more likely to have their reading speed decrease over time, possibly a result of reading fatigue.

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Brain scans could help scientists uncover mechanisms underlying mental fatigue

We all perhaps know the feeling of mental exhaustion, but what does it mean physiologically to have mental fatigue? A new study carried out using brain scans could help scientists uncover the neurobiological mechanisms underlying mental fatigue.

10 Dec 2012

Fatigue News and Research

Mayo Clinic residents attribute traffic incidents to fatigue and distress

EMD Serono's L-BLP25 Phase III NSCLC trial does not meet primary endpoint

Study: Half of the benefit of taking sleeping pills comes from the placebo effect

Global travel, climate warming could create right conditions for chikungunya outbreaks in the U.S.

Study investigates muscle weakness in mouse model of Down syndrome

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Iclusig gets FDA approval for two rare blood and bone marrow diseases

FDA approves Novartis Signifor injection for treatment of Cushing's disease

At-home exercise regimen sufficient to increase cancer patients' mobility and reduce fatigue

Massage could ease distress of brain cancer

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Study finds silent reading difficulties in glaucoma patients

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

Brain scans could help scientists uncover mechanisms underlying mental fatigue

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News